AUTHOR=Fang Ruoxin , Gong Jun , Liao Zhengkai 

TITLE=An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1220745

DOI=10.3389/fonc.2023.1220745

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>The pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of NSCLC with rapid progression and poor prognosis, and is resistant to conventional chemotherapy. Most PSC cases have potential targetable genomic alterations. Approximately 7% of PSC patients have BRAF mutations, and the efficacy of dabrafenib and trametinib in BRAF<sup>V600E</sup> mutated PSC is unclear.</p></sec><sec><title>Case presentation</title><p>Our report describes a patient with mutated BRAF<sup>V600E</sup> PSC who underwent surgery and adjuvant chemotherapy early but quickly relapsed. Both chemotherapy and immunotherapy were ineffective for him, combined dabrafenib and trametinib produced a 6-month progression-free survival, and a partial response was observed in the tumor response evaluation. As a result of financial pressure, he stopped taking the targeted drugs, and his disease rapidly progressed.</p></sec><sec><title>Conclusion</title><p>Dabrafenib combined with trametinib provides partial remission in patients with advanced PSC with BRAF<sup>V600E</sup> mutations, and large-scale NGS panels could offer more options for PSC treatment.</p></sec>